Rio Pharmaceuticals is working to gain a better understanding of Alzheimer's disease (AD). At present, there remains no cure or treatment for this disorder. By utilizing innovative diagnostic imagery, we hope to provide earlier and more accurate diagnosis of the disease, particularly in differentiating it from other similar neurodegenerative diseases.
 | Alzheimer's Disease (AD)?Astrocytes are essential mediators of key processes in the CNS, including homeostasis of the synapses, integrity of the cerebrovascular unit, and dynamic interactions with microglial cells. Hypertrophic reactive astrocyte phenotypes, promoted by microglial cells and other microenvironment signaling elements, have been observed in post-mortem AD tissues adjacent to senile plaques, related cortical regions, and within AD animal-model CNS tissues. Attempts to assess astrocyte changes in AD brain by PET imaging have been very limited. Rio Pharmaceuticals is planning to evaluate the ability of RP-115 to detect changes in astrocyte function in Alzheimer's disease patients, and we are supported in this endeavor by theAlzheimer's Disease Discovery Foundation. |
For more information and resources, please go to the Alzheimer’s Association website.